Other

Terbinafine

PBAC's latest decision on Terbinafine: Recommended with restriction (2007). Considered for Treatment of a dermatophyte infection in an Aboriginal or Torres Strait Islander person where topical treatment has failed (for tablets) and Treatment of a fungal or yeast infection in an Aboriginal or Torres Strait Islander person (for cream).

PBAC outcome

Recommended with restriction

Authority Required

ICER (AUD/QALY)

Cost-min

cost-minimisation analysis

Submissions

first 2007

Submissions

2007 → 2007

Eligible population

Aboriginal or Torres Strait Islander person with a dermatophyte infection (for tablets) and Aboriginal or Torres Strait Islander person with a fungal or yeast infection (for cream)

Therapy area: Other
Line of therapy: Later-line
Evidence base: RCT
Primary endpoint: Mycological cure / complete cure, Clinical efficacy
Key trials: SF00411, SF0042, SF0043A, SF0043B, Voravutinon 1992, Widyanto et al 1993, Kazmi et al 1995, Leenutaphong et al 1999, Vermeer et al 1996
Comparator: griseofulvin (tablet); miconazole (cream)
Economic model: CUA for tablets; cost-minimisation for cream
ICER note: No numeric ICER calculated. Tablet submission presented trial-based cost-effectiveness approach with incremental cost <$500 per extra successfully treated patient (not an ICER/QALY). Cream submission presented cost-minimisation approach (CMA, no ICER by design).

Open on full dashboard →